EG19101A - Process for preparing of expression of human proapolipoprotein A.1. - Google Patents

Process for preparing of expression of human proapolipoprotein A.1.

Info

Publication number
EG19101A
EG19101A EG28288A EG28288A EG19101A EG 19101 A EG19101 A EG 19101A EG 28288 A EG28288 A EG 28288A EG 28288 A EG28288 A EG 28288A EG 19101 A EG19101 A EG 19101A
Authority
EG
Egypt
Prior art keywords
proapolipoprotein
expression
preparing
sequence
expression vectors
Prior art date
Application number
EG28288A
Other languages
English (en)
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Application granted granted Critical
Publication of EG19101A publication Critical patent/EG19101A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
EG28288A 1987-05-28 1988-05-26 Process for preparing of expression of human proapolipoprotein A.1. EG19101A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (1)

Publication Number Publication Date
EG19101A true EG19101A (en) 1994-09-29

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
EG28288A EG19101A (en) 1987-05-28 1988-05-26 Process for preparing of expression of human proapolipoprotein A.1.

Country Status (33)

Country Link
US (1) US5059528A (xx)
EP (1) EP0293357B1 (xx)
JP (1) JP2634193B2 (xx)
KR (1) KR970000808B1 (xx)
CN (1) CN1031892C (xx)
AT (1) ATE89006T1 (xx)
AU (1) AU615654B2 (xx)
CA (1) CA1323851C (xx)
CY (1) CY1809A (xx)
CZ (1) CZ283648B6 (xx)
DD (1) DD291093A5 (xx)
DE (1) DE3880739T2 (xx)
DK (1) DK175686B1 (xx)
EG (1) EG19101A (xx)
ES (1) ES2054878T3 (xx)
FI (1) FI100056B (xx)
GB (1) GB8712540D0 (xx)
HK (1) HK137794A (xx)
HU (1) HU204562B (xx)
IE (1) IE62422B1 (xx)
IL (1) IL86480A (xx)
LT (1) LT3600B (xx)
LV (1) LV5288A3 (xx)
NO (1) NO179253C (xx)
NZ (1) NZ224808A (xx)
PL (1) PL158064B1 (xx)
PT (1) PT87562B (xx)
RU (1) RU2009198C1 (xx)
SG (1) SG131594G (xx)
SK (1) SK279166B6 (xx)
SU (1) SU1834904A3 (xx)
UA (1) UA19765A (xx)
ZA (1) ZA883824B (xx)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
JP4236698B2 (ja) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
DE69115926T2 (de) * 1990-11-30 1996-05-30 Monoclonetics Int Verfahren zur diagnose chronischer niedriger rückenschmerzen und nackenschmerzen
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
CA2431210A1 (en) * 2000-12-12 2002-06-20 Lexicon Genetics Incorporated Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
KR20080049066A (ko) * 2005-08-26 2008-06-03 세레니스 쎄라퓨틱스 홀딩 에스에이 유산균에서의 아포지단백질 유전자 생성물의 생성을 위한조성물 및 방법
WO2008104890A2 (en) * 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
ES2727549T3 (es) * 2008-10-03 2019-10-17 Curna Inc Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1
CA3033577A1 (en) 2008-11-10 2010-05-14 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CN102421900B (zh) 2009-03-12 2015-07-22 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
JP5769701B2 (ja) 2009-05-05 2015-08-26 テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 脂質組成物
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
PL2440183T3 (pl) 2009-06-10 2019-01-31 Arbutus Biopharma Corporation Ulepszona formulacja lipidowa
EP2810643A3 (en) 2009-08-14 2015-03-11 Alnylam Pharmaceuticals Inc. Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP3494963A1 (en) 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
CN103096875B (zh) 2010-06-03 2016-08-17 阿尔尼拉姆医药品有限公司 用于递送活性剂的生物可降解脂质
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
DK2767546T3 (en) 2011-02-07 2019-02-04 Cerenis Therapeutics Holding Sa Lipoprotein complexes and their preparation and uses
AU2012315965A1 (en) 2011-09-27 2014-04-03 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted PEGylated lipids
US9610324B2 (en) * 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
SG11201609084QA (en) 2014-05-02 2016-11-29 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2018077159A1 (zh) * 2016-10-27 2018-05-03 中国科学院微生物研究所 氨基酸衰减子的改造方法及其在生产中的应用
ES2984285T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Cargómeros
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
WO2021209823A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
KR20230079132A (ko) 2020-10-01 2023-06-05 아비오닉스 파마 에스에이 안질환을 치료하는 데 사용하기 위한 지질 결합 단백질-기반 복합체를 포함하는 조성물
EP4322746A1 (en) 2021-04-15 2024-02-21 Abionyx Pharma SA Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
WO1987002062A1 (en) 1985-10-04 1987-04-09 Biotechnology Research Partners, Ltd. Recombinant apolipoproteins and methods
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
EP0269260A3 (en) * 1986-10-29 1988-06-22 Biotechnology Research Partners, Ltd. Apoai-ciii-aiv, apoaii apob, apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
PL272698A1 (en) 1989-03-06
AU1672388A (en) 1988-12-01
PL158064B1 (pl) 1992-07-31
JPS6416589A (en) 1989-01-20
NO179253B (no) 1996-05-28
NZ224808A (en) 1990-01-29
IL86480A (en) 1992-08-18
CN88103118A (zh) 1988-12-14
CA1323851C (en) 1993-11-02
NO882341D0 (no) 1988-05-27
EP0293357A1 (fr) 1988-11-30
AU615654B2 (en) 1991-10-10
FI882456A0 (fi) 1988-05-25
DK175686B1 (da) 2005-01-17
LV5288A3 (lv) 1993-10-10
CY1809A (en) 1995-10-20
KR880014110A (ko) 1988-12-22
NO882341L (no) 1988-11-29
US5059528A (en) 1991-10-22
SK363888A3 (en) 1998-07-08
DK289688D0 (da) 1988-05-27
KR970000808B1 (en) 1997-01-20
ZA883824B (en) 1989-02-22
SG131594G (en) 1995-01-13
ATE89006T1 (de) 1993-05-15
DK289688A (da) 1988-11-29
DE3880739D1 (de) 1993-06-09
IE62422B1 (en) 1995-02-08
SK279166B6 (sk) 1998-07-08
HK137794A (en) 1994-12-16
HU204562B (en) 1992-01-28
LTIP828A (en) 1995-02-27
FI100056B (fi) 1997-09-15
RU2009198C1 (ru) 1994-03-15
FI882456A (fi) 1988-11-29
PT87562A (pt) 1989-05-31
HUT47153A (en) 1989-01-30
CZ283648B6 (cs) 1998-05-13
ES2054878T3 (es) 1994-08-16
CN1031892C (zh) 1996-05-29
LT3600B (en) 1995-12-27
PT87562B (pt) 1992-09-30
IE881597L (en) 1988-11-28
GB8712540D0 (en) 1987-07-01
NO179253C (no) 1996-09-04
UA19765A (uk) 1997-12-25
SU1834904A3 (ru) 1993-08-15
DE3880739T2 (de) 1993-08-19
EP0293357B1 (fr) 1993-05-05
JP2634193B2 (ja) 1997-07-23
DD291093A5 (de) 1991-06-20
CZ363888A3 (cs) 1998-02-18
IL86480A0 (en) 1988-11-15

Similar Documents

Publication Publication Date Title
EG19101A (en) Process for preparing of expression of human proapolipoprotein A.1.
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
DE3586189D1 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
ES2089044T3 (es) Fragmento de dna que codifica un polipeptido que presenta actividad nitrilo hidratasa, un transformante que contiene el fragmento de dna y un proceso para la produccion de amidas utilizando el transformante.
SG49097A1 (en) Nucleotide sequences coding for a protein with urease activity
NO177570B (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
EP0395706A4 (en) Production of gonorrheal pi proteins and vaccines
HUT52551A (en) Process for production of neutrophil-activizating factor
EP0546087A4 (xx)
GB9215232D0 (en) Vaccines
FR2556365B1 (fr) Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
ES2088911T3 (es) Gen de la proteasa i de achromobacter y el producto de este gen.
ATE188997T1 (de) Klonierung von malaria-spezifischen dna- sequenzen:isolierung des gens für das 140 kd protein